Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, fibronectin 1 (FN1), and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes. A weak statistical correlation (0.0015 < p < 0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, FN1, and CDKN2A genes.
Background: Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcome, which opens up new avenues for using them in personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in preoperative diagnosis of aggressive variants of papillary thyroid cancer. Methods: The molecular genetic profile (expression levels of 34 different markers and BRAF mutation) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Results: Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, FN1, and CDKN2A. Weak statistical correlation (0.0015< р<0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. Conclusions: The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, the fibronectin and cyclin-dependent kinase inhibitor 2A genes.
We present a clinical case of 22yo patient with diagnosis of pheochoromocytoma complicated with myelodysplastic syndrome as manifestation of paraneoplastic phenomenon. The onset of the disease displays typical clinical picture of pheochromacytoma. After medical examination and survey it was discovered a tumor in left adrenal gland and elevation of metanephrines and normetanephrines. In addition, patient has severe anemia and thrombocytopenia. Sternal punction with morphological examination and immunophenotyping were performed. Patient had consulted by hematologist. After all additional analysis cause of anemia and thrombocytopenia remained unknown and related to presence of tumor.Patient was performed a long-time and vast pre-operative preparation with administration of doxazosin and transfusions of blood and platelet concentrate. In continuation, mass in left adrenal gland was excised with spleen by thoracophrenolaparotomy. Morphology confirmed pheochromacytoma, which has typical histological structure and circulatory disorders. Spleen has no specifical features except of focuses of extramedullar hematopoiesis. Patient has short period of hormone therapy to avoid adrenal crisis on post-operative stage. Also massive transfutions of blood and platelet concentrate was performed due to persisting anemia and thrombocytopenia. There were no manifestations of hemorrhage syndrome after the surgery. Myelodysplastic syndrome was detected 3 month later and manifested itself in form of refractory anemia and severe thrombocytopenia, which persisted for long period and required corrections with therapy and transfusions. Only through 5-year observation after adrenalectomy patient has positive dynamic and leveling of laboratory tests without symptoms of myelodysplastic syndrome.
We present a clinical case of a patient with metachronous primary multiple carcinoma of left kidney (2004) with left adrenal metastasis (2021), occult low-grade follicular thyroid carcinoma with lateral neck lymph node metastasis (2019), central lung cancer (2020), primary hyperparathyroidism with coherent parathyroid adenomas with intrathyroid and typical location.Patient had undergone left-side nephrectomy with bilateral adrenalectomy, double-staged thyroidectomy with parathyroidectomy and selective lateral neck dissection and right-side pulmonectomy with 4 sessions of chemotherapy. Almost 20 years after first operation patient has no signs of tumors recurrence. In addition, patient is undergoing hormone replacement therapy (HRT) of adrenal insufficiency and thyroid hormone suppression therapy.This case represents combination of non-hereditary endocrine neoplasms with multiple carcinomas. It also examples mistakes and difficulties of differential diagnosis of primary adrenal tumors and adrenal metastasis.
Differentiated thyroid cancer (DTC) is a disease with a favorable clinical course and high survival rate compared to other epithelial tumors. The majority of DTC (up to 85 %) is represented by various subtypes of papillary thyroid cancer (PTC). Aggressive forms of PTC characterized by early lymphogenous and hematogenous metastasis, low avidity to radioiodine therapy (RIT), low relapse-free survival rates and high mortality rate compared to other types of PTC occur among them. Preoperative diagnosis of PTC is based on the results of ultrasound (US) examination and fine-needle aspiration biopsy (FNA) with cytological examination of the aspirate. At the same time, the capabilities of cytological examination in determining the histological type of PTC are limited and it does not allow to predict its aggressiveness and plan adequate treatment. Molecular genetic tests of the tumor cytological and morphological material are effective in prognosis of aggressiveness of PTC due to the determination of specific mutations in the BRAF, TERT, RAS genes and the quantitative expression of oncogenic and tumor suppressive microRNAs. Some of these indicators are already used in the morphological classification of tumors of the endocrine system. At the same time, there are contradictory data concerning the connection of the molecular genetic portrait of PTC, the clinical manifestations of its aggressiveness (extrathyroidal invasion, early metastasis, and radioiodine resistance) and its pathomorphological structure. We tried to summarize and analyze the literature data regarding the diagnosis of aggressive variants of PTC.